Newsletter | October 14, 2021

10.14.21 -- FDA Accepts Polpharma's, Coherus' Respective Lucentis BLAs

Featured Editorial
Industry Insights
Industry Trends In Clinical Development Technology

As electronic data sources become embedded in the clinical development process, systems, processes, files, storage, and approvals are moving away from paper and becoming application dependent.

Meeting Diverse Biologics Pipeline Process Development Challenges

The biopharma manufacturing industry has been evolving at an unmatched pace. Understanding and managing diverse molecule challenges is key to ensuring they reach patients safely and efficiently.  

Blazar Platform: Rodent Virus Panel From The BioReliance® Portfolio

Did you know about the alternative rapid method for in vivo mouse, hamster, and rat antibody production (MAP/HAP/RAP) testing? Download our tech note, Blazar Platform: Rodent Virus Panel from the BioReliance Portfolio, to learn more about our novel degenerate polymerase chain reaction (PCR) assay designed for the detection of a broad range of adventitious agents.

Partner Perspectives To De-Risk Commercialization Of Combination Products

Developing an effective drug-device combination product for self-administered biologics is a complex process. A well-executed strategy will help support integration with manufacturing operations and successful drug delivery.

News Headlines
Life Science Leader Magazine

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.